POWERFUL NEWS:

MMRF PRESS RELEASES


Multiple Myeloma Research Foundation (MMRF) Saddened by Loss of Dear Friend and Board Member Edward Jay Phillips


Phillips Fought Courageous Battle Against Multiple Myeloma

Norwalk, CT — April 9, 2011

The Multiple Myeloma Research Foundation (MMRF) mourns the loss of Board Member Edward (“Eddie”) Jay Phillips, who, on April 8, 2011 died of multiple myeloma, an incurable blood cancer. Phillips, son of "Dear Abby" and Creator of Belvedere Vodka, had battled multiple myeloma for nine years.

“Eddie Phillips was a wonderfully caring person and a phenomenal businessman. He will be sadly missed but always remembered for his pioneering leadership, his thoughtful guidance, and his kind and generous spirit. We extend our deepest sympathy to his parents and children, and his family and friends,” said Kathy Giusti, Founder and CEO of the MMRF, and a multiple myeloma patient.

Phillips’ early and significant investment in the MMRF’s affiliate organization, the Multiple Myeloma Research Consortium (MMRC), was a catalyst for the Consortium’s early success in accelerating early-stage clinical trials in multiple myeloma. In addition to his Board governance, Phillips was a member of the Founder’s Circle for the MMRF’s 3, 2, 1: Cure Campaign and, along with his family, took a lead role in fundraising efforts at the MMRF Race for Research – Twin Cities.

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF)
Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $160 million since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org.